Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.

Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S; Southwest Oncology Group/Intergroup Study 9623.

J Clin Oncol. 2007 May 1;25(13):1677-82. Epub 2007 Apr 2.

PMID:
17404368
2.

Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.

Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, Shpall EJ, Rabinovitch R, Zeng C, Barón A, McSweeney PA.

Biol Blood Marrow Transplant. 2006 Feb;12(2):217-25.

3.

Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study.

Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, Zeng C, Baron A, McSweeney PA.

Bone Marrow Transplant. 2005 Sep;36(5):443-51.

PMID:
15995712
4.
5.

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.

Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Barón AE, Jones RB.

Biol Blood Marrow Transplant. 2005 Apr;11(4):297-306.

6.

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.

Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Chao N, Rizzieri D, Gasparetto C, Matthes S, Barón AE, Jones RB.

Clin Cancer Res. 2004 Nov 1;10(21):7136-43.

7.

Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant.

Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, Pellom J, Slat-Vasquez V, McSweeney PA, Bearman SI, Murphy J, Jones RB.

Clin Cancer Res. 2004 Aug 1;10(15):5076-86.

8.
9.

Reduced-intensity allogeneic stem cell transplantation.

Bearman SI.

Curr Hematol Rep. 2003 Jul;2(4):277-86. Review.

PMID:
12901324
10.

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI; Southwest Oncology Group.

J Clin Oncol. 2003 Jul 1;21(13):2466-73.

PMID:
12829664
11.

Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.

Medeiros BC, Kolhouse JF, Cagnoni PJ, Ryder J, Nieto Y, Rabinovitch R, Shpall EJ, Bearman SI, Jones RB, McSweeney PA.

Bone Marrow Transplant. 2003 Jun;31(11):1053-5.

PMID:
12774059
12.

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC.

Blood. 2002 Dec 15;100(13):4337-43. Epub 2002 Aug 1.

PMID:
12393437
13.

Transplantation of ex vivo expanded cord blood.

Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK.

Biol Blood Marrow Transplant. 2002;8(7):368-76.

PMID:
12171483
14.

Renal dysfunction in allogeneic hematopoietic cell transplantation.

Parikh CR, McSweeney PA, Korular D, Ecder T, Merouani A, Taylor J, Slat-Vasquez V, Shpall EJ, Jones RB, Bearman SI, Schrier RW.

Kidney Int. 2002 Aug;62(2):566-73.

15.

Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer.

Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Barón A, Razook C, Matthes S, Bearman SI.

J Clin Oncol. 2002 Feb 1;20(3):707-18.

PMID:
11821452
16.

Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft.

Nieto Y, Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Rabinovitch RA, McSweeney PA.

Bone Marrow Transplant. 2001 Dec;28(11):1083-6.

17.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED.

N Engl J Med. 2001 Dec 6;345(23):1655-9.

18.

Avoiding hepatic veno-occlusive disease: what do we know and where are we going?

Bearman SI.

Bone Marrow Transplant. 2001 Jun;27(11):1113-20. Review.

19.

Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia.

Howrey RP, Martin PL, Driscoll T, Szabolcs P, Kelly T, Shpall EJ, Bearman SI, Slat-Vasquez V, Rubinstein P, Stevens CE, Kurtzberg J.

Bone Marrow Transplant. 2000 Dec;26(11):1251-4.

20.

Status of high-dose chemotherapy for breast cancer: a review.

Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF.

Biol Blood Marrow Transplant. 2000;6(5):476-95. Review.

21.

Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer.

McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W, Ryder J, Steele A, Stoltz J, Russell P, McDermitt J, Hogan C, Murphy J, Shpall EJ.

Blood. 2000 Nov 1;96(9):3001-7.

PMID:
11049977
22.

Peripheral blood stem cell transplantation in breast cancer.

Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McNiece IK.

Baillieres Best Pract Res Clin Haematol. 1999 Mar-Jun;12(1-2):219-32. Review.

PMID:
11000995
23.

High-dose chemotherapy for breast cancer.

Bearman SI.

Lancet. 2000 Aug 12;356(9229):595-6. No abstract available.

PMID:
10950259
24.

Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation.

Nieto Y, Russ P, Everson G, Bearman SI, Cagnoni PJ, Jones RB, Shpall EJ.

Bone Marrow Transplant. 2000 Jul;26(1):109-11.

25.

High-dose chemotherapy for breast cancer: we have not heard the final word.

Bearman SI.

Cancer Invest. 2000;18(5):494-7. No abstract available.

PMID:
10834035
26.

Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.

Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB.

Biol Blood Marrow Transplant. 2000;6(2A):198-203.

PMID:
10816028
27.

Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.

Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman SI, Jones RB.

J Clin Oncol. 2000 May;18(10):2070-80.

PMID:
10811672
28.

Veno-occlusive disease of the liver.

Bearman SI.

Curr Opin Oncol. 2000 Mar;12(2):103-9. Review.

PMID:
10750719
29.

A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.

Nieto Y, Cagnoni PJ, Shpall EJ, Xu X, Murphy J, Vredenburgh J, Chao NJ, Bearman SI, Jones RB.

Clin Cancer Res. 1999 Nov;5(11):3425-31.

30.

Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support.

Johnson DW, Cagnoni PJ, Schossau TM, Stemmer SM, Grayeb DE, Baron AE, Shpall EJ, Bearman SI, McDermitt J, Jones RB.

Bone Marrow Transplant. 1999 Oct;24(7):785-92.

31.

Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.

Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB.

Bone Marrow Transplant. 1999 Jul;24(1):1-4.

32.

Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease.

Nieto Y, Cagnoni PJ, Shpall EJ, Matthes S, Barón A, Jones RB, Bearman SI.

Clin Cancer Res. 1999 Jul;5(7):1731-7.

33.

Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant.

Nieto Y, Ross M, Gianani R, Shpall EJ, Cagnoni PJ, Bearman SI, Jones RB.

Bone Marrow Transplant. 1999 Jun;23(12):1323-4.

34.

Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.

Nieto Y, Xu X, Cagnoni PJ, Matthes S, Shpall EJ, Bearman SI, Murphy J, Jones RB.

Clin Cancer Res. 1999 Apr;5(4):747-51.

35.

Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.

Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, DeBoom T, Barón A, Jones RB.

Clin Cancer Res. 1999 Mar;5(3):501-6.

36.

Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy.

Richardson P, Bearman SI.

Leuk Lymphoma. 1998 Oct;31(3-4):267-77. Review.

PMID:
9869190
37.

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC.

J Clin Oncol. 1998 Oct;16(10):3310-5.

PMID:
9779706
38.

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.

Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC.

Blood. 1998 Aug 1;92(3):737-44. Review.

PMID:
9680339
39.

High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.

Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Barón AE, Ross M, Matthes S, Dunbar SE, Jones RB.

J Clin Oncol. 1998 May;16(5):1661-8.

PMID:
9586876
40.

High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.

Bearman SI, Overmoyer BA, Bolwell BJ, Taylor CW, Shpall EJ, Cagnoni PJ, Mechling BE, Ronk B, Barón AE, Purdy MH, Ross M, Jones RB.

Bone Marrow Transplant. 1997 Dec;20(11):931-7.

41.

Use of stem cell factor to mobilize hematopoietic progenitors.

Bearman SI.

Curr Opin Hematol. 1997 May;4(3):157-62.

PMID:
9209830
42.
43.

Peripheral blood stem cell harvesting and CD34-positive cell selection.

Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB.

Cancer Treat Res. 1997;77:143-57. Review. No abstract available.

PMID:
9071502
44.

Peripheral blood stem cells for autografting.

Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Jones RB.

Annu Rev Med. 1997;48:241-51. Review.

PMID:
9046959
45.

Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience.

Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Ross M, Taffs S, Jones RB.

Semin Oncol. 1996 Dec;23(6 Suppl 15):43-8.

PMID:
8996598
46.

High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results.

Cagnoni PJ, Shpall EJ, Bearman SI, Ross M, Jones RB.

Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S26-9. Review.

PMID:
8899166
47.

Use of amifostine in bone marrow purging.

Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, Capizzi R, Schein PS, Shpall EJ.

Semin Oncol. 1996 Aug;23(4 Suppl 8):44-8.

PMID:
8783666
48.

High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.

Stemmer SM, Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Dufton C, Day T, Taffs S, Hami L, Martinez C, Purdy MH, Arron J, Jones RB.

J Clin Oncol. 1996 May;14(5):1463-72.

PMID:
8622060
49.

Bone marrow metastases.

Shpall EJ, Gee AP, Hogan C, Cagnoni P, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB.

Hematol Oncol Clin North Am. 1996 Apr;10(2):321-43. Review.

PMID:
8707758
50.

High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer.

Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Ross M.

Semin Oncol. 1996 Feb;23(1 Suppl 2):60-7. Review.

PMID:
8614848

Supplemental Content

Loading ...
Support Center